Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

6 November 2025

Pinterest buy-the-dip: ARK bought 521,867 Pinterest (PINS) shares across ARKK, ARKW and ARKF after the stock slid ~20% on weak holiday‑quarter guidance. ^[1]
Biotech push: Earlier this week ARK purchased 162,327 CRISPR Therapeutics (CRSP) shares and 291,001 Beam Therapeutics (BEAM) shares, signaling renewed conviction in gene editing. ^[2]
Trims continue: ARK sold 105,576 Roku (ROKU) shares and 56,095 Robinhood (HOOD) shares; it also reduced Teradyne (TER) exposure. ^[3]
Why Pinterest fell: The company guided Q4 revenue to $1.31–$1.34B, below consensus, amid softer ad spend in North America and tougher competition—sending shares down more than 20%. ^[4]
By the numbers: Pinterest’s Q3 revenue was $1.049B and monthly active users hit a record 600M, highlighting a long‑term growth base despite near‑term pressure. ^[5]

ARK pounces on Pinterest’s earnings-driven slide

ARK’s Wednesday trade disclosure shows the firm bought 521,867 shares of Pinterest across three funds (ARKK, ARKW, ARKF) after the visual discovery platform cratered on guidance. The add looks like a classic Cathie Wood “buy the dip” move: step into high‑conviction names when volatility runs hottest. ^[6]

Pinterest’s post‑earnings sell‑off was sharp and swift. Management projected holiday‑quarter revenue of $1.31–$1.34B, a touch below Wall Street expectations, and flagged softer ad budgets in the U.S. and Canada amid competitive pressure—an outlook that knocked the shares more than 20% at the open. ^[7]

Underneath the headline, though, Pinterest’s Q3 revenue climbed to $1.049B (+17% YoY), and global MAUs reached 600M, an all‑time high—data points ARK likely weighed as it averaged down. ^[8]

A fresh tilt toward gene editing

On Tuesday, ARK boosted its genomics sleeve, purchasing 162,327 shares of CRISPR Therapeutics (split between ARKK and ARKG) and 291,001 shares of Beam Therapeutics. These buys, totaling tens of millions of dollars at reported prices, suggest ARK is leaning back into platforms it views as long‑duration compounding opportunities. ^[9]

ARK also topped up Guardant Health (GH) with 33,823 shares via ARKG, continuing a healthcare/diagnostics theme that has been a recurring counterweight to its higher‑beta tech holdings. ^[10]

Trimming streaming and fintech exposure

To fund buys and rebalance risk, ARK continued paring some long‑time positions:

Roku (ROKU):105,576 shares sold through ARKK, extending a pattern of gradual reductions in the streaming platform. ^[11]
Robinhood (HOOD):56,095 shares sold, a modest trim after recent strength. ^[12]
Teradyne (TER):27,423 shares sold (Tuesday), part of an ongoing lightening in semiconductor test gear exposure. ^[13]

Across the week, ARK also adjusted smaller positions (e.g., Adaptive Biotechnologies, Ionis, Rocket Lab, AeroVironment), consistent with its active, high‑velocity style. ^[14]

Why the Pinterest bet now?

Two data tracks define the setup:

Near‑term pressure: Pinterest’s holiday outlook undershot consensus, and advertisers in key categories have pulled back. Competitive intensity against platforms with broader reach and increasingly sophisticated AI ad stacks remains a headwind. That’s what triggered the 20%+ reset. ^[15]
Long‑term traction: Even so, engagements and users are rising to records (600M MAUs), and revenue is compounding at a mid‑teens clip—an underpinning ARK often prioritizes when it averages down. ^[16]

In other words, ARK appears to be exchanging momentum for time: trimming winners or riskier cyclicals (streaming/fintech) to add duration in platforms (social commerce, gene editing) where it believes the multi‑year payoff outweighs quarter‑to‑quarter noise.

What it means for investors

Expect continued rotation within ARK: The fund’s model is to reprice risk quickly and lean into dislocations. This week’s combo—buy PINS weakness, add CRSP/BEAM strength, trim ROKU/HOOD/TER—fits that playbook. ^[17]
Pinterest remains a battleground: Watch ad‑spend trends into December, product updates for advertisers, and whether MAU gains convert to improved ARPU despite competitive pressure. ^[18]
Biotech catalysts matter: For CRISPR and Beam, upcoming clinical and commercial milestones will drive sentiment; ARK’s adds suggest it wants exposure into that catalyst path. (General context based on trade data and sector dynamics.) ^[19]

Quick trade ledger (Nov 4–5, 2025)

Ticker	Action	Shares	Noted fund(s)
PINS	Buy	521,867	ARKK, ARKW, ARKF ^[20]
CRSP	Buy	162,327	ARKK, ARKG ^[21]
BEAM	Buy	291,001	ARKK, ARKG ^[22]
GH	Buy	33,823	ARKG ^[23]
ROKU	Sell	105,576	ARKK ^[24]
HOOD	Sell	56,095	ARKK ^[25]
TER	Sell	27,423	ARKK ^[26]

Methodology note

Figures reflect ARK Invest’s daily trade disclosures (excluding creations/redemptions and IPO transactions). Share counts and fund attributions are drawn from same‑day compilers (TipRanks, Investing.com, GuruFocus/TradingView). For issuer fundamentals (e.g., Pinterest results), we referenced company filings/press releases and major wire services. ^[27]

Disclosure: This article is for informational purposes only and does not constitute investment advice.

Top 10 AI Stocks to Watch: Cathie Wood

Watch this video on YouTube.

References

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

View all

Under Armour Q3 Revenue Beats Estimates, But Margins and EBITDA Miss Highlight Tough Turnaround
November 6, 2025, 10:47 AM EST. Under Armour (NYSE: UAA) posted Q3 CY2025 revenue of $1.33 billion, topping Street estimates of $1.31 billion but YoY sales fell 4.7%. Adjusted EPS of $0.04 beat consensus by $0.02, yet Adjusted EBITDA came in at $31.81 million vs $67.04 million expected, a sizable miss. The company guided full-year EPS at $0.04 midpoint, well below analysts' view. Operating margin compressed to 1.3% from 12.4% a year ago. Free Cash Flow was -$90.32 million (vs -$367.2 million a year earlier). Constant-currency revenue declined about 6% in the quarter, with modest signs of brand momentum in North America per CEO Kevin Plank. Analysts see revenue flat next year, implying a cautious near-term outlook for top-line growth.
Prestige Consumer Healthcare (PBH) Beats Q2 Earnings; Near-Term Outlook Cautious
November 6, 2025, 10:44 AM EST. Prestige Consumer Healthcare (PBH) posted Q2 earnings of $1.07 per share, ahead of the Zacks Consensus of $0.97 and marking a +10.3% surprise. Revenue came in at $274.11 million, beating the consensus by 6.87% versus year-ago revenue of $283.79 million. Over the last four quarters, PBH has beaten EPS estimates three times. The stock has slid about 23.4% year to date, underperforming the S&P 500 (+15.6%). The firm carries a Zacks Rank #4 (Sell), signaling near-term underperformance unless management provides a positive earnings outlook on the call. For the coming quarter, current estimates are $1.23 on $294.9 million in revenue; FY guidance sits at $4.51 on $1.1 billion in revenue.
Arhaus, Inc. (ARHS) Beats Q3 EPS and Revenue; Zacks Rank #2 Buy Ahead of Outlook
November 6, 2025, 10:42 AM EST. Arhaus, Inc. (ARHS) reported Q3 earnings of $0.09 per share, beating the Zacks Consensus by $0.01 and posting a +12.5% surprise from a year ago. Revenue was $344.57 million, topping estimates by about 1%. The company has exceeded EPS estimates in three of the last four quarters and has beat revenue estimates in two of the last four. Year-to-date, ARHS has risen about 3.8%, underperforming the S&P 500's gain of ~15.6%. Ahead of the call, the Zacks Rank remains #2 Buy. For the coming quarter, consensus is $0.10 per share on $348.02 million in revenue, and full-year guidance sits at $0.45 on $1.36 billion in revenue. Management commentary will shape the near-term outlook.
Epam (EPAM) Q3 Earnings Beat; Revenue Rises, But Stock Faces Mixed Outlook
November 6, 2025, 10:40 AM EST. Epam (EPAM) reported Q3 earnings of $3.08 per share, beating the Zacks Consensus Estimate of $3.02 and delivering a +1.99% surprise. Revenue reached $1.39 billion, ahead of the consensus by 1.44% versus $1.17 billion a year ago. The company has topped estimates in all four of the past four quarters. Despite the beat, shares are down about 31.2% year-to-date as the broader market climbs. Outlook signs show a current-quarter consensus of $2.90 on $1.38 billion in revenue and a full-year view of $11.11 on $5.41 billion. Market focus will shift to management commentary for earnings trajectory and any revisions to the IT Services outlook and estimates.
Cars.com Q3 Results: Revenue In Line, EBITDA Beat, Margin Expansion
November 6, 2025, 10:38 AM EST. Cars.com (NYSE:CARS) reported a Q3 that largely met expectations on revenue and adjusted earnings, while delivering a clear EBITDA beat and margin expansion. Revenue was $181.6 million, essentially in line with consensus of $181.4 million. Adjusted EPS came in at $0.48 vs $0.49 expected. Adjusted EBITDA totaled $54.63 million, ahead of the $53.51 million estimate, with a 30.1% EBITDA margin and Operating Margin of 9.3% (up from 6.4% a year ago). Free Cash Flow Margin jumped to 29% from 10.2%. Dealer Customers rose to 19,526, up 271 YoY. The company's current Market Capitalization is about $639.6 million. Looking ahead, analysts see about 2.4% revenue growth over the next 12 months, with modest long-term growth versus peers.

Cathie Wood Loads Up on Pinterest After 20% Plunge; ARK Adds CRISPR, Trims Roku, Robinhood & Teradyne (Nov 6, 2025)

ARK pounces on Pinterest’s earnings-driven slide

A fresh tilt toward gene editing

Trimming streaming and fintech exposure

Why the Pinterest bet now?